Halozyme Therapeutics. has been granted a patent for modified PH20 hyaluronidase polypeptides that demonstrate enhanced stability and activity. The patent includes specific claims regarding amino acid modifications and sequence identity related to the unmodified PH20 polypeptide. GlobalData’s report on Halozyme Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Halozyme Therapeutics, was a key innovation area identified from patents. Halozyme Therapeutics's grant share as of July 2024 was 51%. Grant share is based on the ratio of number of grants to total number of patents.
Modified ph20 hyaluronidase polypeptides with enhanced properties
The patent US12060590B2 describes a modified PH20 polypeptide characterized by specific amino acid modifications compared to an unmodified PH20 polypeptide. The unmodified polypeptide is defined by amino acid sequences from a specified group (SEQ ID NOs: 3, 7, and 32-66). The modifications include replacements, deletions, or insertions, particularly focusing on an amino acid replacement at residue 307, which can be one of several specified amino acids (G, K, N, Q, S, T, V, W, or Y). The modified polypeptide must maintain at least 91% sequence identity to the unmodified versions, with some claims specifying a higher threshold of 95%. Additional claims highlight the modified polypeptide's enhanced stability under denaturing conditions and increased hyaluronidase activity.
Further claims expand on the characteristics of the modified PH20 polypeptide, including its solubility, potential post-translational modifications (such as glycosylation), and the possibility of being conjugated to polymers like dextran or polyethylene glycol (PEG). The patent also covers the creation of pharmaceutical compositions that incorporate the modified polypeptide, which may include various therapeutically active agents. Methods for treating hyaluronan-associated diseases or conditions, including inflammatory diseases and tumors, are also outlined, emphasizing the therapeutic potential of the modified PH20 polypeptide in clinical applications.
To know more about GlobalData’s detailed insights on Halozyme Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
